Takeda Pharmaceutical Co. Ltd.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. carries a market capitalization of 44.42B, placing it among publicly traded companies globally. Its enterprise value stands at 68.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Takeda Pharmaceutical Co. Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. has 1.58B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 18.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 548.98 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 68.18B versus a market cap of 44.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.35, indicating elevated leverage, while an interest coverage ratio of 6.43 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a negative return on equity (ROE) of -2.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.10, reflecting losses generated across the asset base. The company generates approximately 526,426.95 in revenue per employee across its workforce of 47,242.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Takeda Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. recorded 177.04M in income tax expense. The company reported a pretax loss of -701.39M and -879.98M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Takeda Pharmaceutical Co. Ltd.'s stock has gained approximately 47.55% over the past 52 weeks. The 50-day moving average sits at 32.26, while the 200-day moving average is 29.89.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. generated 24.87B in revenue and converted that into -879.98M in net income, yielding earnings per share of -0.55. EBITDA reached 3.63B, while operating income came in at 2.59B.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. holds 2.84B in cash and equivalents against 26.60B in total debt, resulting in a net debt position of 24.12B. Total book value stands at 40.69B, with working capital of 2.08B providing operational flexibility.

Takeda Pharmaceutical Co. Ltd. produced 4.45B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.83B in capital expenditures, free cash flow totaled 2.62B - equivalent to 1.66 per share.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of -3.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. paid dividends of 0.57 per share. The dividend payout ratio of -102.30 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.42, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Takeda Pharmaceutical Co. Ltd. shareholders.

Takeda Pharmaceutical Co. Ltd.'s most recent stock split took place on March 28, 1988 with a 10:11 split ratio.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. has an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.